SCHEMBL4201848

SCHEMBL4201848

COc1cc(NS(C)(=O)=O)ccc1S(=O)(=O)Nc1ccccc1CNC(C)CC1CCCCC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.42
LMNA P02545 3/20 0.42
KDM4E B2RXH2 3/20 0.42
MAPT P10636 3/20 0.42
ACLY P53396 1/20 0.40
TSHR P16473 2/20 0.39
CASP1 P29466 2/20 0.39
CASP7 P55210 2/20 0.39
HSD17B10 Q99714 2/20 0.39
ALDH1A1 P00352 3/20 0.39
GRM4 Q14833 1/20 0.38
HTT P42858 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
CYP17A1 P05093 1/20 0.38
PKM P14618 1/20 0.38
GLA P06280 2/20 0.37
SLC22A1 O15245 1/20 0.37
ABCC4 O15439 1/20 0.37
KDM1A O60341 1/20 0.37
NR1I2 O75469 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4197884 0.89 ALDH1A1 (0.48) LMNAMAPTALDH1A1GRM4HTT
SCHEMBL4185858 0.88 ALDH1A1 (0.44) SMN1; SMN2LMNAKDM4EMAPTALDH1A1
SCHEMBL4188167 0.88 MAPT (0.44) SMN1; SMN2LMNAKDM4EMAPTTSHR
SCHEMBL4200124 0.85 PIK3CG (0.45) KDM4EKMT2A
SCHEMBL4190400 0.84 KDM4E (0.52) SMN1; SMN2LMNAKDM4EMAPTTSHR
SCHEMBL4189913 0.83 KDM4E (0.45) SMN1; SMN2LMNAKDM4EMAPTALDH1A1
SCHEMBL4708411 0.83 GRM4 (0.40) SMN1; SMN2LMNAKDM4EMAPTACLY
SCHEMBL4190913 0.82 KDM4E (0.50) SMN1; SMN2LMNAKDM4EMAPTTSHR
SCHEMBL4197632 0.80 KDM4E (0.39) SMN1; SMN2LMNAKDM4EMAPTALDH1A1
SCHEMBL14343941 0.79 SMN1; SMN2 (0.33) SMN1; SMN2LMNAKDM4EMAPTTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1879877-B1 ANTIMICROBIAL AGENTS RANBAXY LAB LTD (IN) 2013-01-02 EP claimed
US-8076370-B2 Antimicrobial agents RANBAXY LABORATORIES LIMITED (IN) 2011-12-13 US claimed
US-20090215764-A1 Antimicrobial agents RANBAXY LABORATORIES LIMITED (IN) 2009-08-27 US claimed
EP-1879877-B1 ANTIMICROBIAL AGENTS RANBAXY LAB LTD (IN) 2013-01-02 EP disclosed
US-8076370-B2 Antimicrobial agents RANBAXY LABORATORIES LIMITED (IN) 2011-12-13 US disclosed
US-20090215764-A1 Antimicrobial agents RANBAXY LABORATORIES LIMITED (IN) 2009-08-27 US disclosed
EP-1879877-A2 ANTIMICROBIAL AGENTS Ranbaxy Laboratories Limited (IN) 2008-01-23 EP disclosed
WO-2006117762-A2 ANTIMICROBIAL AGENTS RANBAXY LABORATORIES LIMITED (IN) 2006-11-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215764-A1 Antimicrobial agents TUFM, RPS17, HARS1 SMN1; SMN2 3369/4885LMNA 2332/4885KDM4E 3328/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.